On September 3, 2024 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, reported that senior leadership plans to present at the following conferences (Press release, Iovance Biotherapeutics, SEP 3, 2024, View Source [SID1234646296]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo Healthcare Conference
Fireside Chat: September 4, 2024 at 3:45 p.m. ET
Boston, MA
Baird Global Healthcare Conference
Fireside Chat: September 10, 2024 at 2:35 p.m. ET
New York, NY
H.C. Wainwright Global Investment Conference
Presentation: September 11, 2024 at 11:00 a.m. ET
New York, NY
The live and archived webcasts will be available at View Source

On September 3, 2024 INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, reported that management will participate in the following investor conferences in September and October, 2024 (Press release, INmune Bio, SEP 3, 2024, View Source [SID1234646295]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Baird 2024 Global Healthcare Conference

New York, NY; September 10-11, 2024
Presentation Time: Tuesday, September 10 at 8:30-9:00 AM Eastern Time
Location: Session III, Empire Ballroom B, Mezzanine Level

On September 3, 2024 iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, reported that CEO and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., and Chief Financial Officer, Felipe Duran, will participate in upcoming investor conferences (Press release, iBioPharma, SEP 3, 2024, View Source [SID1234646294]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Brenner will give a virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference, held at the Lotte New York Palace Hotel in New York City, September 9-11, 2024. The presentation will be available on-demand from 7 a.m., Sept. 9, at View Source and following for 30 days. A replay of the webcast will be available in the investor section of iBio’s website.

iBio will also be attending the 2024 Cantor Global Healthcare Conference in New York City, September 17-19, 2024.

To schedule a one-on-one meeting with Dr. Brenner or Mr. Duran at either of the conferences, please e-mail [email protected].

On September 3, 2024 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported the Company’s participation in the following upcoming investor and industry conferences to be held in September 2024 (Press release, Genprex, SEP 3, 2024, View Source [SID1234646293]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright 26th Annual Global Investment Conference

Conference Dates: September 9-13, 2024

Presentation Date: On-demand September 9-11, 2024 in the conference portal (virtual)

Presenter: Ryan Confer, Genprex’s President, Chief Executive Officer and Chief Financial Officer

Mr. Confer will virtually deliver an overview of the Company’s pioneering gene therapies for cancer and diabetes and will be available for virtual meetings with investors through the conference platform.

Event: Chardan’s 8th Annual Genetic Medicines Conference

Dates: September 30 – October 1, 2024

Location: Westin Grand Central in New York, NY

Company Participant: Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing

Mr. Gallagher will be available for in-person meetings with conference attendees.

For those interested in meeting Genprex management during these conferences, please request a meeting through the conference portal or reach out to Investor Relations at [email protected].

On September 3, 2024 FibroGen, Inc. (NASDAQ: FGEN) reported that the Company will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY (Press release, FibroGen, SEP 3, 2024, View Source [SID1234646292]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thane Wettig, Chief Executive Officer of FibroGen, will deliver a company presentation on Tuesday, September 10 at 3:00 PM ET at the Lotte New York Palace Hotel. A live webcast of the presentation will be available here.

FibroGen’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright. A replay of the presentation will be posted, when available, to the FibroGen website on the Events & Presentation page of the investors section for 90 days.